Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus

Show other versions (1)

Bibliographic Details
Main Authors:	Paresh Ved, Samrat Shah
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2013-01-01
Series:	Indian Journal of Endocrinology and Metabolism
Online Access:	http://www.ijem.in/article.asp?issn=2230-8210;year=2013;volume=17;issue=1;spage=178;epage=178;aulast=Ved

Similar Items

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
by: Paresh Ved, et al.
Published: (2012-01-01)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over three months in patients with type 2 diabetes mellitus′
by: Vishal Mundra
Published: (2012-01-01)

Treatment Compliance with Fixed-Dose Combination of Vildagliptin/Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational Study
by: Grigorios Rombopoulos, et al.
Published: (2015-01-01)

Vildagliptin and its role in the treatment of diabetes mellitus
by: Yury Shavkatovich Khalimov
Published: (2010-09-01)

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly
by: Sicras-Mainar A, et al.
Published: (2014-06-01)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
by: Hyun Jeong Jeon, et al.
Published: (2011-10-01)

Metformin and/or vildagliptin mitigate type II diabetes mellitus induced-oxidative stress: The intriguing effect
by: Hayder M Al-Kuraishy, et al.
Published: (2020-01-01)

Systematic review of clinical and economic effectiveness of vildagliptin in type 2 diabetic patients with poor glycemic control on monotherapy with metformin
by: Alima Almadiyeva, et al.
Published: (2018-12-01)

Vildagliptin: the known and unknown
by: L. Y. Morgunov
Published: (2016-12-01)

Surfing the vildagliptin tsunami
by: Karthik Balachandran
Published: (2020-01-01)

Budget impact of vildagliptin
by: Orietta Zaniolo, et al.
Published: (2008-09-01)

Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients
by: Cakirca M, et al.
Published: (2014-02-01)

Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet
by: Serge Halimi, et al.
Published: (2008-06-01)

Possibilities of vildagliptin in optimal control of type 2 diabetes mellitus
by: V.I. Pankiv
Published: (2019-09-01)

Vildagliptin: optimal control in type 2 diabetes mellitus treatment
by: Alexander Sergeevich Ametov
Published: (2015-10-01)

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment
by: Lukashevich V, et al.
Published: (2013-01-01)

Clinical evidence and mechanistic basis for vildagliptin&#39;s effect in combination with insulin
by: Schweizer A, et al.
Published: (2013-02-01)

Bullous Pemphigoid Induced by Vildagliptin
by: Bengür Taşkıran Bahattin, et al.
Published: (2016-12-01)

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
by: Jong Ho Kim, et al.
Published: (2016-04-01)

Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats.
by: Nattayaporn Apaijai, et al.
Published: (2014-01-01)

Vildagliptin: a new oral treatment for type 2 diabetes mellitus
by: Chantal Mathieu, et al.
Published: (2008-12-01)

Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
by: Hara Kousoulakou, et al.
Published: (2017-09-01)

Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
by: Klempfner Robert, et al.
Published: (2012-06-01)

Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes
by: Jin-Sun Chang, et al.
Published: (2013-02-01)

Effects of 18-month Vildagliptin Treatment on Portal Vein Pressure and Hepatosteatosis
by: Cumali KARATOPRAK, et al.
Published: (2019-10-01)

Efficacy and pathogenetic justification for the use of vildagliptin in patients with type 2 diabetes mellitus
by: V.I. Pankiv
Published: (2019-10-01)

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
by: Dejager S, et al.
Published: (2012-05-01)

Pathogenetic substantiation and effectiveness of vildagliptin use inpatients with diabetes mellitus type 2
Published: (2009-09-01)

Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
by: Michał Wiciński, et al.
Published: (2020-03-01)

Mild acute pancreatitis with vildagliptin use
by: Ravikant Saraogi, et al.
Published: (2012-01-01)

A Prospective Observational Study to Compare the Efficacy and Adverse Effects of Glimepiride and Vildagliptin Added to Metformin in Type 2 Diabetes Mellitus
by: Biswanath Sharma Sarkar, et al.
Published: (2019-02-01)

Glycemic effects of vildagliptin in patients with type 2 diabetes before, during and after the period of fasting in Ramadan
by: Line P. Malha, et al.
Published: (2014-02-01)

The Efficacy of Vildagliptin in Korean Patients with Type 2 Diabetes
by: Jun Sung Moon, et al.
Published: (2013-02-01)

Vildagliptin Treatment on the Portal Venous Pressure and Hepatosteatosis in Patients with Type 2 Diabetes Mellitus
by: Cumali KARATOPRAK, et al.
Published: (2018-01-01)

Chromium (III) complexes of metformin, dapagliflozin, vildagliptin and glimepiride potentiate antidiabetic activity in animal model
by: Aktar, F., et al.
Published: (2021)

Determination of the vildagliptin intermediate enantiomer by chiralce-columns
by: Weina LI, et al.
Published: (2017-06-01)

Vildagliptin: the first innovative DDP-4 inhibitor
by: Edvin Villkhauer
Published: (2010-09-01)

Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin
by: Andrea Tura, et al.
Published: (2015-01-01)

Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats.
by: Qian Zhang, et al.
Published: (2017-01-01)

Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats
by: Ashish Kumar Sharma, et al.
Published: (2014-12-01)